Key Drivers
- Strong gross margin
- Very low ROE
- High market multiples
AIAI Summary
LFST has shifted from a growth story to an operational‑improvement investment—its strong free cash flow and rising adjusted EBITDA underpin upside, but the critical risk is the 25M‑share secondary (no proceeds) combined with clinician retention/refinancing exposure, so only invest if you have conviction in sustained margin expansion and orderly absorption of the overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong gross margin
- •Very low ROE
- •High market multiples
LFST combines solid gross margins and robust free cash flow with moderate leverage, but suffers from negligible net profitability, large intangibles, and stretched market multiples that limit shareholder return potential.
Price Behavior
Key Price Behavior Insights:
- •Below moving average
- •Mildly oversold
- •Support-critical
LFST is in a short-term pullback—closing below the last month average ($6.85) at $6.40 with an RSI ~28 (mildly oversold), key support $6.33 must hold to avoid further downside toward lower levels while resistance sits at $7.30–$7.40.
Close below last month average ($6.85) with
Sentiment & News
Key News Insights:
- •EPS beat
- •Large insider sale
- •Analyst optimism
LifeStance reported Q4 EPS of $0.03 beating estimates while a concurrent 25M-share secondary by insiders (company receives no proceeds) creates a mixed signal for investors.
The earnings beat supports a constructive outlook, but the large secondary offering may pressure the stock and temper near-term upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings